

**LAHIVE
&
COCKFIELD**
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINCIC, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPERT
JOHN D. LANZA
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. McKENNA
VINCENT P. LOCCISANO
JAMES M. McKENZIE
CYNTHIA M. GILBERT
LEIGH J. MARTINSON

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DiGIORGIO
CYNTHIA L. KANIK, Ph.D.

PATENT AGENTS
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK
JAMES H. VELEMA
JACOB G. WEINTRAUB

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
W. ELANA WANG
MEAGHAN L. RICHMOND, Ph.D.

* Admitted in TX only
** Admitted in CT only

JAW

April 15, 2005

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RECEIVED
APR 21 2005
OIPE/JCYS

Re: U.S. Patent Application No.: 10/031,841
For: *HUMAN HOMOLOGUE OF BOVINE NEUROENDOCRINE SECRETORY
PROTEIN, NESP55, POLYNUCLEOTIDES AND USES THEREOF LINKED
WITH OBESITY*
Inventors: Douglas C. Fraser, *et al.*
Filed: January 22, 2002
Our Ref. No.: KNI-004CPUS

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB/08;
3. Copies of selected references cited in PTO Form SB/08 (13);
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on:	
4-15-05	
Date	
<i>Giulio A. DeConti, Jr.</i>	
Giulio A. DeConti, Jr., Esq.	Registration No. 31,503

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Giulio A. DeConti, Jr.
Giulio A. DeConti, Jr., Esq.
Registration No. 31,503
Agent for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Douglas C. Fraser, *et al.*

Serial No.: 10/031,841

Filed: January 22, 2002

For: *HUMAN HOMOLOGUE OF BOVINE
NEUROENDOCRINE SECRETORY PROTEIN,
NESP55, POLYNUCLEOTIDES AND USES
THEREOF LINKED WITH OBESITY*

Attorney Docket No.: KNI-004CPUS

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

4-15-05

Date of Signature and of Mail Deposit

By:


Giulio A. DeConti, Jr., Esq.
Registration No. 31,503
Agent for Applicants

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed. The copy of the cited U.S. patent (Reference ID No. A1) is not enclosed with this statement. Copies of non-patent literature (Reference ID Nos. A2-B4) are enclosed in accordance with 37 CFR 1.98.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant/s understand/s that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Giulio A. DeConti, Jr., Esq.
Registration No. 31,503
Agent for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: April 15, 2005

GAD/EAH/CEH/les
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/031,841
				Filing Date	January 22, 2002
				First Named Inventor	Douglas C. Fraser
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	KNI-004CPUS


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	6,608,025 B1	08-19-2003	Fraser, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	A2	CHRISTIE <i>et al.</i> , "Identification of kex2-related proteases in chromaffin granules by partial amino acid sequence analysis," <i>J Biol Chem.</i> , 1991 Aug 25;266(24):15679-83.		
	A3	EGGER <i>et al.</i> "Different degrees of processing of secretogranin II in large dense core vesicles of bovine adrenal medulla and sympathetic axons correlate with their content of soluble PC1 and PC2," <i>Neurosci Lett.</i> , 1993 Sep 3;159(1-2):199-201.		
	A4	FULLER <i>et al.</i> "Intracellular targeting and structural conservation of a prohormone-processing endoprotease," <i>Science</i> , 1989 Oct 27;246(4929):482-6.		
	A5	HAMBLIN, <i>et al.</i> "Primary structure and functional characterization of a human 5-HT _{1D} -type serotonin receptor," <i>Mol Pharmacol.</i> , 1991 Aug;40(2):143-8.		
	A6	HAYWARD <i>et al.</i> "Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins," <i>Proc Natl Acad Sci U S A.</i> , 1998 Dec 22;95(26):15475-80.		
	A7	ISCHIA <i>et al.</i> Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT _{1B} receptor antagonist activity. <i>J Biol Chem.</i> 1997 Apr 25;272(17):11657-62.		
	A8	JIN <i>et al.</i> "Characterization of the human 5-hydroxytryptamine _{1B} receptor," <i>J Biol Chem.</i> , 1992 Mar 25;267(9):5735-8.		
	A9	KIRCHMAIR <i>et al.</i> "Differential subcellular distribution of PC1, PC2 and furin in bovine adrenal medulla and secretion of PC1 and PC2 from this tissue," <i>Neurosci Lett.</i> , 1992 Aug 31;143(1-2):143-5.		
	A10	LEVY <i>et al.</i> "Molecular cloning of a human serotonin receptor (S12) with a pharmacological profile resembling that of the 5-HT _{1D} subtype," <i>J Biol Chem.</i> , 1992 Apr 15;267(11):7553-62.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/031,841
				Filing Date	January 22, 2002
				First Named Inventor	Douglas C. Fraser
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	KNI-004CPUS
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	B1	LOVISETTI-SCAMIHORN <i>et al.</i> "Pig splenic nerve: peptides derived from chromogranins by proteolytic processing during axonal transport," <i>Regul Pept.</i> , 1999 Jan 1;79(1):63-7.		
	B2	LOVISETTI-SCAMIHORN <i>et al.</i> "Relative amounts and molecular forms of NESP55 in various bovine tissues," <i>Brain Res.</i> , 1999 May 22;829(1-2):99-106.		
	B3	SIGAFOOS <i>et al.</i> "Novel peptides from adrenomedullary chromaffin vesicles," <i>J Anat.</i> , 1993 Oct;183 (Pt 2):253-64.		
	B4	WISE <i>et al.</i> "Expression of a human proprotein processing enzyme: correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site," <i>Proc Natl Acad Sci U S A.</i> , 1990 Dec;87(23):9378-82.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--